ZhuCBinJadeedHGabrielliS, et al. Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience. Clin Exp Dermatol. 2024;49(10):1227-1231. doi:10.1093/ced/llae145
2.
KocaturkESainiSSRubeizCJBernsteinJA.Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring. J Allergy Clin Immunol Pract. 2022;10(12):3099-3116. doi:10.1016/j.jaip.2022.09.038
3.
MaurerMCasaleTBSainiSS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184-194. doi:10.1016/j.jaci.2024.01.028
4.
MaurerMMetzMAndersonJ, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025;80(8):2178–2186. doi:10.1111/all.16598
5.
MetzMGiménez-ArnauAHideM, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792
